The Drug That Can't Be Approved Because Ageing Isn't a Disease
The card imagines a licensed medicine that slows ageing. The largest obstacle isn't pharmacological. It's regulatory.
The card imagines a licensed medicine that slows ageing. The largest obstacle isn't pharmacological. It's regulatory.
The catch
Drug approval requires an indication — a condition the drug treats. Regulators approve medicines for diabetes, for hypertension, for cancer.
No major regulator recognises ageing as an indication. So a compound that slowed ageing across every system could not be approved for doing so, because there is no box to tick.
This is not a technicality. It shapes what gets funded, because no company invests in a trial with no approvable endpoint.
The workaround
The TAME trial — Targeting Aging with Metformin — was designed specifically to solve this. Rather than testing whether metformin extends life, it tests whether it delays the onset of multiple age-related diseases simultaneously: cardiovascular disease, cancer, dementia.
If a drug delays all of them at once, the argument goes, it must be acting on ageing rather than on any one condition. That would establish a precedent regulators could work with.
The trial has faced years of funding difficulty, because metformin is generic and nobody stands to profit from proving it works.
What's actually in the pipeline
Metformin — decades of safety data, and observational evidence that diabetics taking it sometimes outlive non-diabetics, which is peculiar. Whether that survives proper trial is unknown.
Rapamycin — the most reliable lifespan extender in mammals ever tested. It also suppresses immune function, so dosing schedules that capture the benefit without the risk are the active question.
Senolytics — clearing senescent cells. Strong animal results, modest early human results.
GLP-1 agonists — the weight-loss drugs. They're producing unexpected benefits across cardiovascular disease, kidney disease and possibly addiction and dementia. Whether that's weight loss or something more fundamental is being investigated seriously.
The honest odds
A drug approved specifically for ageing by 2037: unlikely, mostly because of the regulatory path rather than the science.
A drug approved for something narrower that turns out to slow ageing broadly: considerably more likely, and arguably how it will actually happen.
What it would change
Not lifespan first — healthspan. The years at the end currently spent in decline.
The economic argument is stronger than most people realise. A drug that delayed the onset of age-related disease by even a few years would save more in healthcare costs than almost any intervention available, because most lifetime medical spending occurs in the final years.
Longevity Drug Approved is card #298 in the Legacy Domination collection — a trading card game where every card is a real moment in history, and a few that haven't happened yet. [Explore the collection →]
The Card Behind This Story
Longevity Drug Approved
#298
Want the cards behind these stories?
Join the waitlist and we'll notify you at launch.
Join the Waitlist